Hikma completes acquisition of Custopharm

London, 21 April 2022 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces that it has completed its acquisition of Custopharm Inc. (‘Custopharm’) from Water Street Healthcare Partners (‘Water Street’), following approval from the US Federal Trade Commission.

Press Release Corporate 21 April 2022

As previously announced on 27 September 2021, Hikma has acquired Custopharm for an initial cash consideration of $375 million on a debt and cash-free basis, with a further $50 million in contingent consideration payable upon the achievement of certain commercial milestones.

Hikma is the second-largest supplier by volume of generic sterile injectable medicines used by US hospitals and health care providers. The combination with Custopharm enhances Hikma’s R&D capabilities and pipeline and expands Hikma’s differentiated US portfolio to close to 130 commercialised injectable medicines – a more than fivefold increase over the last decade.

Transaction highlights and strategic rationale:

  • Complements Hikma’s product portfolio and pipeline, adding up to 13 approved products and additional pipeline products
  • Enhances Hikma’s R&D capabilities, adding an experienced scientific team of dedicated R&D professionals with a proven ability to develop and commercialise complex sterile injectable products and a state-of-the-art R&D laboratory in California
  • Maintains Hikma’s strong regulatory track record. Custopharm has consistently obtained regulatory approval for new products with four first-to-market FDA ANDA approvals, including one CGT exclusivity for Calcitonin Salmon, which was launched in May 2021

Siggi Olafsson, Chief Executive Officer of Hikma, commented:

“The acquisition of Custopharm immediately strengthens our already strong US injectables business by adding an attractive and profitable portfolio of marketed products, an exciting pipeline of future opportunities, and a first-class scientific team with a strong regulatory track record. This acquisition is highly complementary to our existing business and places us in an excellent position to better serve the growing needs of hospitals, doctors and patients. I am excited to welcome the team at Custopharm to Hikma as we continue to grow and strengthen our Injectables business.”

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.